Buyback yield (TTM)
N/A
Shareholder yield (TTM)
N/A
5Y share count change
17.1%
Buyback spend (TTM)
N/A
Cumulative buybacks
$22.44M
Key takeaways
- Diluted share count is up 17.1% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM repurchases used about 0% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Alnylam Pharmaceuticals (ALNY)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Alnylam Pharmaceuticals (ALNY)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Alnylam Pharmaceuticals (ALNY)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Alnylam Pharmaceuticals (ALNY)
Latest: $0.00
Overview
The 2025 reading of Alnylam Pharmaceuticals (ALNY) buyback spend is $0.00.
Through 2015–2025 (10 years), Alnylam Pharmaceuticals buyback spend delivered a -100.0% annualised rate; with a net decline across the window.
Alnylam Pharmaceuticals buyback spend peaked at $15.99M in 2014; the latest annual figure is $0.00 in 2025 (100.0% below peak).
Across the available history, buyback spend reached its high of $15.99M in 2014 and its low of $0.00 in 2002.
Alnylam Pharmaceuticals Buyback Spend 2025: $0.00
Alnylam Pharmaceuticals buyback spend in 2025 was $0.00.
Alnylam Pharmaceuticals Buyback Spend 2024: $0.00
Alnylam Pharmaceuticals buyback spend in 2024 was $0.00.
Alnylam Pharmaceuticals Buyback Spend 2023: $0.00
Alnylam Pharmaceuticals buyback spend in 2023 was $0.00.
Alnylam Pharmaceuticals Buyback Spend 2022: $0.00
Alnylam Pharmaceuticals buyback spend in 2022 was $0.00.
Alnylam Pharmaceuticals Buyback Spend 2021: $0.00
Alnylam Pharmaceuticals buyback spend in 2021 was $0.00.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $0.00 | $348.24M | −$348.24M | — | 0.13B | +5.5% | |
| 2024 | $0.00 | $272.08M | −$272.08M | — | 0.13B | +2.2% | |
| 2023 | $0.00 | $221.68M | −$221.68M | — | 0.12B | +2.6% | |
| 2022 | $0.00 | $230.65M | −$230.65M | — | 0.12B | +2.7% | |
| 2021 | $0.00 | $165.72M | −$165.72M | — | 0.12B | +3.0% | |
| 2020 | $0.00 | $139.87M | −$139.87M | — | 0.11B | +5.2% | |
| 2019 | $0.00 | $174.84M | −$174.84M | — | 0.11B | +8.6% | |
| 2018 | $3.47M | $157.75M | −$154.28M | 0.05% | 0.10B | +11.1% | |
| 2017 | $257.00K | $92.82M | −$92.56M | 0.00% | 0.09B | +5.8% | |
| 2016 | $596.00K | $75.53M | −$74.93M | 0.02% | 0.09B | +1.9% | |
| 2015 | $378.00K | $45.78M | −$45.41M | 0.00% | 0.08B | +13.1% | |
| 2014 | $15.99M | $33.06M | −$17.07M | 0.21% | 0.07B | +20.7% | |
| 2013 | $1.39M | $20.70M | −$19.31M | 0.03% | 0.06B | +22.4% | |
| 2012 | $359.00K | $12.36M | −$12.00M | 0.04% | 0.05B | +18.6% | |
| 2011 | $0.00 | $16.80M | −$16.80M | — | 0.04B | +0.9% | |
| 2010 | $0.00 | $19.34M | −$19.34M | — | 0.04B | +1.0% | |
| 2009 | $0.00 | $20.17M | −$20.17M | — | 0.04B | +1.4% | |
| 2008 | $0.00 | $18.03M | −$18.03M | — | 0.04B | +6.3% | |
| 2007 | $0.00 | $14.47M | −$14.47M | — | 0.04B | +21.2% | |
| 2006 | $0.00 | $8.30M | −$8.30M | — | 0.03B | +45.3% | |
| 2005 | $0.00 | $0.00 | $0.00 | — | 0.02B | +84.7% | |
| 2004 | $0.00 | $4.11M | −$4.11M | — | 0.01B | +1160.9% | |
| 2003 | $0.00 | $0.00 | $0.00 | — | 0.00B | +184.5% | |
| 2002 | $0.00 | $0.00 | $0.00 | — | 0.00B | — |
- 2025$0.00
- 2024$0.00
- 2023$0.00
- 2022$0.00
- 2021$0.00
- 2020$0.00
- 2019$0.00
- 2018$3.47M
- 2017$257.00K
- 2016$596.00K
- 2015$378.00K
- 2014$15.99M
- 2013$1.39M
- 2012$359.00K
- 2011$0.00
- 2010$0.00
- 2009$0.00
- 2008$0.00
- 2007$0.00
- 2006$0.00
- 2005$0.00
- 2004$0.00
- 2003$0.00
- 2002$0.00
Buybacks vs stock-based compensation for Alnylam Pharmaceuticals (ALNY)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Buybacks vs dividends (share of cash returned) for Alnylam Pharmaceuticals (ALNY)
How Alnylam Pharmaceuticals splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $641.34M (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation